Search

Displaying results 9461 - 9470 of 10000 in total
  1. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand _ex vivo_.

  2. Drug

    PEP0101

    go.drugbank.com/drugs/DB18572
    Experimental

    PEP0101 is a nanocomplex consisting of elastin-like polypeptides and a small interfering RNA (siRNA) designed to down-regulate the expression of EVI1 oncogene in cancer cells.

    Synonyms: Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.
  3. Drug

    BJ-001

    go.drugbank.com/drugs/DB18585
    Investigational

    BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.

  4. Drug

    INH-A21

    go.drugbank.com/drugs/DB18598
    Experimental

    INH-A21 is a human staphylococcal immunoglobulin

  5. Drug

    APPD

    go.drugbank.com/drugs/DB18603
    Experimental

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    ISTH0036

    go.drugbank.com/drugs/DB18606
    Investigational

    ISTH0036 is a synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA

  7. Drug

    P-42 peptide

    go.drugbank.com/drugs/DB18610
    Experimental

    P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein

  8. Drug

    IDUA-RTB

    go.drugbank.com/drugs/DB18612
    Experimental

    RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB).

  9. Drug

    AOC 1001

    go.drugbank.com/drugs/DB18620
    Investigational

    Delpacibart (AOC 1001) is being investigated in a global study for the treatment of Myotonic Dystrophy type 1 (DM1) in clinical trial NCT06411288

  10. Drug

    SLN500

    go.drugbank.com/drugs/DB18636
    Experimental

    SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA